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Abstract: By using triangular silver (Ag) nanoparticle array, a localized surface plasmon reso-
nance (LSPR) nanosensor was fabricated and shown to sense serum p53 protein in vitro, which 
is involved in head and neck squamous cell carcinoma (HNSCC). The nanosensor consists of a 
triangular Ag nanoparticles array with single particle dimension of 120 nm in-plane width and 
45 nm out-of-plane height. When examined using LSPR nanobiosensor, the results indicated 
significant difference in LSPR shifts (∆λmax) between HNSCC patient and control. Although 
there is need for precise quantification and large-scale prospective, this report shows that the 
LSPR nanobiosensor provides a promising platform with attractive advantages for serological 
diagnosis or molecular diagnosis in tumor, such as HNSCC. This is the first clinical application 
of the LSPR nanosensor in HNSCC.
Keywords: localized surface plasmon resonance, p53 protein, biosensor, oral squamous-cell 
carcinoma
Introduction
p53 protein is a 53-kDa nuclear tumor suppressor protein present in humans and is 
encoded by the TP53 gene. When tumors develop, point mutations at the TP53 gene 
can lead to overexpression of p53 proteins, which contribute to continuous cell 
  division and canceration. Overexpression of p53 has been reported in 60% of laryngeal 
  carcinomas, 37% of hypopharyngeal carcinomas, and 52% of tongue carcinomas.1–3 
With the   mortality and disintegration of tumor cells, p53 protein released from cancer 
cells will enter into the circulation. The serum p53 protein level in carcinoma of colon, 
lung, and pancreas was significantly increased compared with normal controls.4–6 
It was reported that 68 out of 75 patients (91%) with head and neck squamous cell 
  carcinoma (HNSCC) had detectable serum p53 protein in the preoperative blood.7 The 
detection of serum p53 protein may play an important role in serological diagnosis of 
tumor, including HNSCC. The serum p53 protein level can be examined mainly by 
  enzyme-linked immunosorbent assay (ELISA). ELISA has advantages of sensitivity, 
reproducibility, and stability. Its applications are constrained for   high-titer anti-p53 anti-
body interference of some noncancer patients and it is a   time-consuming, complicated 
and inconvenient procedure. To address these considerations, sensitive, easy to use, and 
cost-effective portable biosensors that are capable of providing continuous monitoring 
and rapid detection of serum p53 protein need to be developed.
The localized surface plasmon resonance (LSPR)-based nanobiosensor is a new type 
of optical biosensor technique that combines nanotechnology with optical   biosensor International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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technology. LSPR is one of the specific characteristics of 
metallic or metalized   nanostructured materials, such as noble 
metal nanoparticles. It can be excited when the incident pho-
ton frequency is resonant with the collective oscillation of the 
conduction electrons.8 Transmission peaks of LSPR-related 
spectra are sensitive to the electric medium on the surface 
of noble metals. It demonstrates that the applicability of this 
biosensor can be more defined in a wide range of fields, such 
as medical, food safety, environmental monitoring, and drug 
screening.9–11
The aim of the present study is to apply the developed 
LSPR biosensor based on the triangular silver (Ag) nanopar-
ticles for the detection of p53 protein levels in samples from 
HNSCC patients. This is the first case report of the LSPR 
sensor that responds to serum p53 protein of a cancer patient 
and a healthy control.
Materials and methods
Materials
11-Mercaptoundecanoic acid (11-MUA) and 1-octanethiol 
(1-OT) were purchased from Sigma Aldrich (St. Louis, MO). 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-
chloride (EDC) and sulfo-N-hydroxysuccinimide (S-NHS) 
were purchased from Aladdin (Shanghai, China). A mouse 
monoclonal p53 antibody raised against full-length p53 of 
human origin was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).
Absolute ethanol and phosphate-buffered saline (PBS; 
10 mM, pH 7.4) were purchased from Beijing Biosynthesis 
Biotechnology Company (Beijing, China). The buffer used 
in the experiments was prepared using double-distilled 
water.
Patients and sample
Two serum samples from one HNSCC patient and one healthy 
control were collected from West China Hospital of Stoma-
tology, Sichuan University, Chengdu, People’s Republic of   
China, in 2009. Informed consent documents were signed 
prior to the study.
The HNSCC patient was diagnosed by biopsy preopera-
tively and had no prior radiotherapy or chemotherapy. One 
venous blood sample was obtained from the patient before 
operation and another from a healthy volunteer as healthy 
control.
Once blood was collected, it was allowed to stand 
at 37°C, for 2 h, and then was centrifuged at 800 g for 
10 min. The serum was collected and stored at −80°C until 
analysis.
Preparation and functionalization of the 
LsPr-based nanobiosensor
The sensor chip in this work was produced using nano-
sphere lithography (NSL) technology. K9 glass substrates 
(Juke Co., Chengdu, China) were cleaned by piranha solution 
(1:3 30% H2O2/H2SO4) at 80°C for 30 min. Then they were 
rinsed with copious amounts of second distilled water and 
sonicated for 60 min in 5:1:1 H2O/NH4OH/30% H2O2. After 
7 µL of nanosphere solution (Duke Scientific, Palo Alto, CA) 
was spin coated onto the substrate, 50 nm Ag was deposited 
by a thermal evaporation system (C-Vac400-I; C-Vac Inc., 
Chengdu, China). Finally, the Ag nanostructures on the sub-
strate for the experiments were formed after the nanospheres 
were removed by ultrasonic in ethanol.
We measured the surface modality of the samples by 
using a scanning electron microscope (S-4800; Hitachi, 
Tokyo, Japan). The triangular Ag nanoparticles have dimen-
sions of 120 nm in-plane widths, 400 nm period of the 
nanoparticles array as measured by SEM, and 45 nm out-
of-plane heights as measured by a sidestep apparatus. Fig-
ure 1 shows the SEM micrograph of the nanoparticles.
Functionalization of the sensor chip is a multistep process 
that provides the surface for specific detection applications. 
First, a self-assembled monolayer of 2 mM 1-OT/1 mM 
11-MUA acid was formed onto the surface by incubation 
in an ethanoic solution for 24 h. After thoroughly rins-
ing and drying, the biochip was then incubated in 20 mM 
EDC/10 mM S-NHS/2 µg/mL monoclonal mouse anti-
p53 solution for 12 h in the dark to link the antibody to 
the surface of nanoparticles. EDC, a zero-length coupling 
agent, can couple the amine groups on the antibody to the 
carboxyl groups on 11-MUA. This process is facilitated 
Figure 1 seM image of topography of the triangular Ag nanoparticles fabricated by 
nanosphere lithography (×50,000).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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by the presence of S-NHS. The samples were thoroughly 
rinsed with 0.01 M PBS buffer and then dried by blowing 
N2 with high pressure. Finally, an Ag p53 nanobiosensor was 
formed. A schematic illustration of the prefunction for the 
  nanoparticles surface is shown in Figure 2.
The serum samples were then rinsed using 0.01 M PBS 
buffer, and 40 µL of diluted serums from human serum were 
spotted onto the surface of this functionalized biochip for 
150 min (Figure 3).
spectroscopy and observation
The integrated LSPR sensor used in this study is our home-
built system (Figure 4). The peak wavelength of LSPR 
extinction spectrum (λmax) excited by the Ag triangular 
nanoparticles array was measured and recorded using a UV-
visible spectroscope (Sciencetech 9005; Sciencetech, Ottawa, 
Canada). Practical measurements of the UV-visible extinction 
spectra were carried out using a fiber-coupled spectrometer 
(USB4000; Ocean Optics, Dunedin, FL) and a CCD detector 
(Koan Electro-Optics Co., Shanghai, China).
The measuring procedure was divided into three steps: 
1) collecting the reference light without sensor chip, 
2) collecting the background noise to increase the accu-
racy, and 3) measuring the transmission from the sensor chip 
without any analysis. The sensor’s extinction spectra can be 
caculated by software. With these processes, the sensor’s 
extinction spectra can be easily obtained by in computer, 
and we can record and compare the data of different sensor 
chips. The shift toward longer wavelengths is referred to as a 
redshift and is denoted as (+), whereas the shift toward shorter 
wavelengths is referred to as a blueshift and is denoted as 
(−). The system resolution of this biosensor is about 5 nm. 
When the   wavelength shift of the absorbance peak is less 
than + 5 nm, it   indicates that the   biosensor cannot sense the 
medium at the   nanoparticles–solution interface.
Results
LSPR spectra of the Ag nanosensors in each processing step 
are shown in Figures 5 and 6, with the incidence wavelength 
ranging from 400 to 700 nm. The resulting extinction spectrum 
of the bare Ag nanoparticles is depicted in Figure 5A, where 
the LSPR λmax was measured to be 588.2 nm (Figure 5A). 
The LSPR λmax of Ag   nanoparticles after modification with 
11-MUA/1-OT was 623.5 nm (Figure 5B). The LSPR λmax 
shift corresponding to this step was a 35.3-nm redshift. After 
p53 antibody attachment, the λmax of modified Ag nanopar-
ticles chip was 673.84 nm (Figure 5C). There is an additional 
50.34-nm redshift from the second peak. The LSPR shifts 
from 673.84 to 676.08 nm during the serum incubation for 
the control serum, and then ∆λmax was a 2.24-nm shift (Fig-
ure 5D). Redshift volume of 2.24 nm is less than 5 nm, which 
demonstrates that LSPR sensor chip shows no response to 
control serum.
The measured extinction spectrum of serum from the 
HNSCC patient is shown in Figure 6. The λmax of the   biochip 
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Figure 2 A schematic illustration of the prefunction for the nanoparticles surface. 
Four chemical structures: A) eDC⋅HCl; B) s-NHs; C) 1-OT; D) 11-MUA. E) A 
mixed monolayer of 1-OT and 11-MUA is formed on the exposed surfaces of the Ag 
nanoparticles. eDC is a zero length coupling agent and can couple the amine groups 
on the antibody to the carboxyl groups on 11-MUA.
Figure 3 A schematic representation of the LsPr-based nanobiosensor depicting its 
exposure to human samples.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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before and after incubation with HNSCC serum sample was 
671.41 and 689.08 nm, respectively (Figure 6C, D). There 
was a 17.67-nm shift, which is a significant shift to dem-
onstrate the p53 level change in the sample. The peak shift 
for the HNSCC patient is more than 5 nm, which is larger 
than that of the control. These results suggest that the LSPR 
nanobiosensor can respond to p53 protein in HNSCC patient’s 
serum and illustrate the difference of serum p53 level of the 
HNSCC patient and healthy control.
Discussion
The optical characteristics of the nanochip were indexed 
by the wavelength shift of the absorbance peak, namely 
∆λmax.8 A significant change was observed in the wavelength 
Light source 
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waste bottle
PC 
Collimating 
lens
Focus
lens
Figure 4 schematic representation of integrate LsPr nanobiosensor. The sensor chip is loaded by substrate holder (on the top of the system).
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Figure 5 Design of the LsPr biosensor for serum p53 protein detection in control. A) Ag nanoparticles before chemical modification, λmax = 588.2 nm; B) Ag nanoparticles 
after modification with 11-MUA/1-OT, λmax = 623.5 nm; C) The chip with 2 µg/mL mouse monoclonal p53 antibody, λmax = 673.84 nm; D) The biochip after incubation with 
control serum sample, λmax = 676.08 nm. All extinction measurements were collected at room temperature.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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shift using our LSPR-based nanochip. We found that the 
extinction spectroscopy varies with each step of surface 
functionalization for the Ag nanoparticles. In addition, the 
results showed   a significant difference in LSPR shifts (∆λmax) 
between the HNSCC patient and control. LSPR sensor chip 
showed no response to control serum, whereas it showed 
obvious response to HNSCC serum. This suggested a differ-
ent concentration of p53 protein level between two groups. 
Chow et al demonstrated that the mean serum p53 protein 
concentration of the HNSCC patients was 59.45 pg/mL, 
which was significantly higher than that of the healthy donors 
(16.4 pg/mL) when examined using ELISA.7 This result is 
similar to our experimental results. Moreover, our LSPR 
method provides free-labeling process, which cannot be 
obtained using ELISA.
These results indicate the future prospects of LSPR sensor 
chip application in tumor serological diagnosis. However, 
further investigation is necessary to evaluate the feasibil-
ity of clinical application of this LSPR biosensor system. 
A large-sample clinical random case-control study with a 
long follow-up period is in preparation.
This experiment is the first case report of the LSPR sensor, 
which responded to serum p53 protein of a HNSCC patient 
and a healthy control. The triangular Ag nanoparticles have 
dimensions of 120 nm in-plane width, 45 nm out-of-plane 
height, and 400-nm period of the nanoparticles array. The 
size of Ag triangle is different from that used in published 
research. Ag nanoparticles can produce stronger localized 
surface plasmon than gold nanoparticles, although they 
are more easily oxidized. In addition, the LSPR peak of Ag 
particles is also easier to detect.12 The chip can be preserved 
in a vacuum plastic bag as long as 1 month. In a normal envi-
ronment at room temperature, the storage period is 1 week. 
Meanwhile, the regeneration can be achieved by removing 
the Ag nanoparticles on the substrate, which is advanta-
geous because the substrate can be thoroughly cleaned so 
as to improve the fabrication quality of the chips for future 
experimental use.
All the extinction measurements were carried out at room 
temperature, and all the samples were exposed in ordinary 
room conditions with dust and vapor, which illustrates that 
our Ag particle-based sensor can be used in an open space 
without any sterilization process. The real-time LSPR-shift 
assay had a similar response to a commercial surface plasmon 
resonance instrument, but it demonstrated less interference 
from bulk refractive index. In addition, LSPR possesses greater 
spatial resolution, both lateral and normal, when compared 
with SPR.
Conclusion
For the first time, we have proposed a LSPR-based 
  nanobiosensor for the detection of p53 protein from an 
HNSCC patient and a control. We discovered dramatic 
differences in LSPR shifts (∆λmax) between the HNSCC 
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Figure 6 Design of the LsPr biosensor for serum p53 protein detection in HNsCC. A) Ag nanoparticles before chemical modification, λmax = 584.13 nm; B) Ag nanoparticles 
after modification with 11-MUA/1-OT, λmax = 610.9 nm; C) The chip with 2 µg/mL mouse monoclonal p53 antibody, λmax = 671.41 nm; D) The biochip after incubation with 
HNsCC serum sample, λmax = 689.08 nm. All extinction measurements were collected at room temperature.International Journal of Nanomedicine
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patient and control. Further large-scale prospective study is 
worthwhile to evaluate the value of our nanobiosensor for 
serological diagnosis or molecular diagnosis in tumors, such 
as HNSCC. However, we anticipate that this technology will 
be a promising candidate for point-of-care diagnosis and 
therefore promote the development of personalized medicine 
in a simple and rapid format.
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